Sample . | Age . | Sex . | Main Nevus Size* . | Method for NCM Diagnosis . | NCM Symptoms . | Prior Therapy . | Tissue Mmelanocytic Lesion Site . | Tumor Mutation . | Follow-up Time . |
---|---|---|---|---|---|---|---|---|---|
P01S | 1 y 5 mo | Male | G2 | MRI/autopsy | Hydrocephalus | Sorafenib, temozolomide, and radiation | Spinal cord | NRAS p.Q61R | Autopsy |
P09B | 6 y | Male | L2 | MRI/autopsy | Seizure | Brain surgery | Frontal lobe | NRAS p.Q61K | Autopsy |
C76N | 1 y 9 mo | Male | G2 | MRI | No | Surgery | Skin | NRAS p.Q61K | 1 y 5 mo |
PD1N | 2 y 5 mo | Male | G2 | MRI | Tethered cord | Surgery | Skin | NRAS p.Q61K | 2 y |
Sample . | Age . | Sex . | Main Nevus Size* . | Method for NCM Diagnosis . | NCM Symptoms . | Prior Therapy . | Tissue Mmelanocytic Lesion Site . | Tumor Mutation . | Follow-up Time . |
---|---|---|---|---|---|---|---|---|---|
P01S | 1 y 5 mo | Male | G2 | MRI/autopsy | Hydrocephalus | Sorafenib, temozolomide, and radiation | Spinal cord | NRAS p.Q61R | Autopsy |
P09B | 6 y | Male | L2 | MRI/autopsy | Seizure | Brain surgery | Frontal lobe | NRAS p.Q61K | Autopsy |
C76N | 1 y 9 mo | Male | G2 | MRI | No | Surgery | Skin | NRAS p.Q61K | 1 y 5 mo |
PD1N | 2 y 5 mo | Male | G2 | MRI | Tethered cord | Surgery | Skin | NRAS p.Q61K | 2 y |
Main nevus size categorization according to Krengel et al.10
Sample . | Age . | Sex . | Main Nevus Size* . | Method for NCM Diagnosis . | NCM Symptoms . | Prior Therapy . | Tissue Mmelanocytic Lesion Site . | Tumor Mutation . | Follow-up Time . |
---|---|---|---|---|---|---|---|---|---|
P01S | 1 y 5 mo | Male | G2 | MRI/autopsy | Hydrocephalus | Sorafenib, temozolomide, and radiation | Spinal cord | NRAS p.Q61R | Autopsy |
P09B | 6 y | Male | L2 | MRI/autopsy | Seizure | Brain surgery | Frontal lobe | NRAS p.Q61K | Autopsy |
C76N | 1 y 9 mo | Male | G2 | MRI | No | Surgery | Skin | NRAS p.Q61K | 1 y 5 mo |
PD1N | 2 y 5 mo | Male | G2 | MRI | Tethered cord | Surgery | Skin | NRAS p.Q61K | 2 y |
Sample . | Age . | Sex . | Main Nevus Size* . | Method for NCM Diagnosis . | NCM Symptoms . | Prior Therapy . | Tissue Mmelanocytic Lesion Site . | Tumor Mutation . | Follow-up Time . |
---|---|---|---|---|---|---|---|---|---|
P01S | 1 y 5 mo | Male | G2 | MRI/autopsy | Hydrocephalus | Sorafenib, temozolomide, and radiation | Spinal cord | NRAS p.Q61R | Autopsy |
P09B | 6 y | Male | L2 | MRI/autopsy | Seizure | Brain surgery | Frontal lobe | NRAS p.Q61K | Autopsy |
C76N | 1 y 9 mo | Male | G2 | MRI | No | Surgery | Skin | NRAS p.Q61K | 1 y 5 mo |
PD1N | 2 y 5 mo | Male | G2 | MRI | Tethered cord | Surgery | Skin | NRAS p.Q61K | 2 y |
Main nevus size categorization according to Krengel et al.10
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.